02344nas a2200253 4500000000100000008004100001653001800042653001200060653001100072653002000083653002400103653001100127653001700138100001400155700001500169700002200184700001100206245007700217856005200294300001000346490000700356520171300363022001402076 2012 d10aSkin Diseases10aleprosy10aHumans10aDonor Selection10aDermatologic Agents10aBrazil10aBlood Donors1 aWambier C1 aPereira CS1 aPrado Júnior BPA1 aFoss N00aBrazilian blood donation eligibility criteria for dermatologic patients. uhttp://www.scielo.br/pdf/abd/v87n4/v87n4a12.pdf a590-50 v873 a

A focused and commented review on the impact of dermatologic diseases and interventions in the solidary act of donating blood is presented to dermatologists to better advise their patients. This is a review of current Brazilian technical regulations on hemotherapeutic procedures as determined by Ministerial Directive #1353/2011 by the Ministry of Health and current internal regulations of the Hemotherapy Center of Ribeirão Preto, a regional reference center in hemotherapeutic procedures. Criteria for permanent inaptitude: autoimmune diseases (>1 organ involved), personal history of cancer other than basal cell carcinoma, severe atopic dermatitis or psoriasis, pemphigus foliaceus, porphyrias, filariasis, leprosy, extra pulmonary tuberculosis or paracoccidioidomycosis, and previous use of etretinate. Drugs that impose temporary ineligibility: other systemic retinoids, systemic corticosteroids, 5-alpha-reductase inhibitors, vaccines, methotrexate, beta-blockers, minoxidil, anti-epileptic, and anti-psychotic drugs. Other conditions that impose temporary ineligibility: occupational accident with biologic material, piercing, tattoo, sexually transmitted diseases, herpes, and bacterial infections, among others.

DISCUSSION:

Thalidomide is currently missing in the teratogenic drugs list. Although finasteride was previously considered a drug that imposed permanent inaptitude, according to its short halflife current restriction of 1 month is still too long. Dermatologists should be able to advise their patients about proper timing to donate blood, and discuss the impact of drug withdrawal on treatment outcomes and to respect the designated washout periods.

 a1806-4841